留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《中国儿童系统性红斑狼疮诊断与治疗指南》解读

王琳 宋红梅

王琳, 宋红梅. 《中国儿童系统性红斑狼疮诊断与治疗指南》解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0018
引用本文: 王琳, 宋红梅. 《中国儿童系统性红斑狼疮诊断与治疗指南》解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0018
WANG Lin, SONG Hongmei. Interpretation of Chinese Guidelines for the Diagnosis and Treatment of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0018
Citation: WANG Lin, SONG Hongmei. Interpretation of Chinese Guidelines for the Diagnosis and Treatment of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0018

《中国儿童系统性红斑狼疮诊断与治疗指南》解读

doi: 10.12290/xhyxzz.2022-0018
基金项目: 

国家重点研发计划(2021YFC2702004)

详细信息
    通讯作者:

    宋红梅,E-mail:songhm1021@126.com

  • 中图分类号: R593.24;R593.2

Interpretation of Chinese Guidelines for the Diagnosis and Treatment of Childhood-onset Systemic Lupus Erythematosus

Funds: 

National Key Research and Development Program of China(2021YFC2702004)

  • 摘要: 鉴于儿童系统性红斑狼疮的诊断和治疗较成人更具复杂性,中华医学会儿科学分会免疫学组联合指南方法学专家及《中华儿科杂志》编辑部制定了我国首部《儿童系统性红斑狼疮诊断与治疗指南》。该指南是对2011年我国《儿童系统性红斑狼疮诊疗建议》的延续,依据循证实践,结合中国具体国情,指南回答了12个儿童系统性红斑狼疮诊断、评估、治疗和预后管理等方面的关键临床问题,以期为各级医疗机构和参与儿童系统性红斑狼疮诊疗及管理的专业人员提供指导,规范系统性红斑狼疮患儿的诊断、合理用药及长期管理。
  • [1] Lisnevskaia L, Murphy G, Isenberg D.Systemic lupus erythematosus[J].Lancet, 2014, 384:1878-1888.
    [2] 中华医学会儿科学分会免疫学组,《中华儿科杂志》编辑委员会.儿童系统性红斑狼疮诊疗建议[J].中华儿科杂志, 2011, 49:506-514.
    [3] Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus[J]. Arthritis Rheumatol, 2019, 71:1400-1412.
    [4] Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus:the SHARE initiative[J]. Ann Rheum Dis, 2017, 76:1788-1796.
    [5] Groot N, de Graeff N, Marks SD, et al.European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis:the SHARE initiative[J]. Ann Rheum Dis, 2017, 76:1965-1973.
    [6] Wu CY, Li CF, Wu QJ, et al. Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX:Clinical Features and Survival of Childhood-Onset Systemic Lupus Erythematosus in China[J]. Chin Med J (Engl), 2017, 130:1276-1282.
    [7] World Health Organization. WHO Handbook for Guideline Development[M/OL].2nd Edition.(2014-12-18)[2022-01-10]. https://www.who.int/publications/i/item/9789241548960
    [8] 蒋朱明, 詹思延, 贾晓巍, 等. 制订/修订《临床诊疗指南》的基本方法及程序[J]. 中华医学杂志, 2016, 96:250-253.
    [9] Brouwers MC, Kho ME, Browman GP, et al. AGREE II:advancing guideline development, reporting and evaluation in health care[J].CMAJ, 2010, 182:E839-E842.
    [10] Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care:the RIGHT statement[J].Ann Intern Med, 2017, 166:128-132.
    [11] Levisky Y, Broide M, Kagan S, et al. Performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in a paediatric population-a multicentre study[J]. Rheumatology (Oxford), 2021, 60:5142-5148.
    [12] Fonseca AR, Felix Rodrigues MC, Sztajnbok FR, et al. Comparison among ACR1997, SLICC and the new EULAR/ACR classification criteria in childhood-onset systemic lupus erythematosus[J].Adv Rheumatol, 2019, 59:20
    [13] 中华医学会儿科学分会肾脏学组.狼疮性肾炎诊治循证指南(2016)[J].中华儿科杂志, 2018, 56:88-94.
    [14] Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis[J]. Ann Rheum Dis, 2012, 71:1771-1782.
    [15] Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis[J]. Arthritis Care Res (Hoboken), 2012, 64:797-808.
    [16] Ma H, Dong J, Wang L, et al. Impact of follow-up visits on disease outcome in Chinese systemic lupus erythematosus[J]. Clin Rheumatol, 2018, 37:101-105.
    [17] Ma H, Dong J, Wang L, et al. Impact of follow-up visits on disease outcome in Chinese systemic lupus erythematosus[J]. Clin Rheumatol, 2018, 37:101-105.
    [18] Gladman DD, Ibañez D, Ruiz I, et al. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients:data from an observational cohort study[J]. J Rheumatol, 2013, 40:630-633.
    [19] Ibañez D, Gladman DD, Touma Z, et al. Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time[J]. J Rheumatol, 2011, 38:60-63.
    [20] 冷晓梅, 曾小峰.糖皮质激素在系统性红斑狼疮患者合理应用的专家共识[J].中华内科杂志, 2014, 53:502-504.
    [21] Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults[J]. Rheumatology (Oxford), 2018, 57:e1-e45.
    [22] 中华医学会儿科学分会儿童用药委员会.糖皮质激素在儿童风湿病中应用专家共识(下)[J].中华儿科杂志, 2019, 57:16-20.
    [23] 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J].中华内科杂志, 2020, 59:172- 185.
    [24] GlaxoSmithKline plc. GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above[EB/OL].(2019-04-26)[2022-01- 10].https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-of-benlystafor-intravenous-use-in-children-with-lupus-aged-five-years-and-above/.
    [25] 国家药品监督管理局.首个系统性红斑狼疮(SLE)儿童药物新适应证在中国获批[EB/OL].(2020-12-07)[2022-01- 10].https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20201207163143123.html.
    [26] 国家药品监督管理局.国家药监局批准注射用泰它西普上市[EB/OL].(2021-03- 12)[2022-01-10]. https://www.nmpa.gov.cn/directory/web/nmpa/zhuanti/ypqxgg/gggzjzh/20210312165618199.html.
    [27] Trindade C, Carneiro M, Bonfa E, et al. An Update on the Management of ChildhoodOnset Systemic Lupus Erythematosus[J]. Pediatric Drugs, 2021, 23:331-347.
    [28] Mok CC, Cheung TT, Lo WH. Minimal mesangial lupus nephritis:a systematic review[J]. Scand J Rheumatol, 2010, 39:181-189.
    [29] Srivastava P, Abujam B, Misra R, et al. Outcome of lupus nephritis in childhood onset SLE in North and Central India:single-centre experience over 25 years[J]. Lupus, 2016, 25:547-557.
    [30] Smith E, Al-Abadi E, Armon K, et al. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis[J]. Lupus,2019, 28:613-620.
    [31] Baskin E, Ozen S, Cakar N, et al. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis[J]. Pediatr Nephrol, 2010, 25:111-117.
    [32] Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis[J]. Cochrane Database Syst Rev, 2018, 6:CD002922.
    [33] Mao Y, Yin L, Huang H, et al. Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy[J]. J Int Med Res, 2019, 47:105-113.
    [34] Pereira M, Muscal E, Eldin K, et al. Clinical presentation and outcomes of childhoodonset membranous lupus nephritis[J]. Pediatr Nephrol, 2017, 32:2283-2291.
    [35] Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient[J]. Clin J Am Soc Nephrol, 2009, 4:1417-1422.
    [36] Tang KT, Tseng CH, Hsieh TY, et al. Induction therapy for membranous lupus nephritis:a systematic review and network meta-analysis[J]. Int J Rheum Dis, 2018, 21:1163-1172.
    [37] Swan JT, Riche DM, Riche KD, et al. Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis[J]. J Investig Med, 2011, 59:246-258.
    [38] Govoni M, Hanly JG. The management of neuropsychiatric lupus in the 21st century:still so many unmet needs?[J]. Rheumatology, 2020, 59:52-62.
    [39] Lauvsnes MB, Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies[J].J Neurol,2012, 259:622-629.
    [40] Bertsias GK,Ioannidis JP,Aringer M,et al. EULAR recommendations for the management of systemic lupuserythematosus with neuropsychiatric manifestations:report of a task force of the EULAR standingcommittee for clinical affairs[J]. Ann Rheum Dis,2010, 69:2074-2082.
    [41] Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of neuropsychiatric systemiclupus erythematosus:current approaches and future perspectives[J]. Drugs, 2016, 76:459-483.
    [42] Narváez J, Ríos-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus:current clinical evidence[J].Semin Arthritis Rheum, 2011, 41:364- 372.
    [43] Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specificinhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus:combined results from two phase III trials[J]. Ann Rheum Dis, 2012, 71:1833-1838.
    [44] De Marchi G, Quartuccio L, Bond M, et al. Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2017, 35:1056.
    [45] JI J,WU Y,MENG Y,et al. JAK-STAT signaling mediates the senescence of bone marrowmesenchymal stem cells from systemic lupus erythematosus patients[J]. Acta Biochim Biophys Sin (Shanghai), 2017, 49:208-215.
    [46] Mok CC. The Jakinibs in systemic lupus erythematosus:progress and prospects[J]. Expert Opin Investig Drugs, 2019,28:85-92.
    [47] Littlejohn E, Marder W, Lewis E, et al. The ratio of erythrocyte sedimentation rate to Creactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever[J]. Lupus, 2018, 27:1123-1129.
    [48] Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients:susceptibility factors and preventive strategies[J]. Lupus, 2013,22:1286-1294.
    [49] Gupta D, Zachariah A, Roppelt H, et al. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide:a survey of US rheumatologists and the review of literature[J]. J Clin Rheumatol,2008,14:267- 272.
    [50] Quaglia M, Merlotti G, De andrea M, et al. Viral Infections and Systemic Lupus Erythematosus:New Players in an Old Story[J]. Viruses, 2021, 13:277.
    [51] Pringe A, Trail L, Ruperto N, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus:an under-recognized complication?[J]. Lupus,2007,16:587-592.
    [52] Ravelli A, Minoia F, Davì S, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis:a European league against rheumatism/American college of rheumatology/paediatric rheumatology international trials organisation collaborative initiative[J]. Ann Rheum Dis,2016, 75:481-489.
    [53] Abdirakhmanova A, Sazonov V, Mukusheva Z, et al. Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus:A Systematic Review of the Diagnostic Aspects[J]. Front Med (Lausanne),2021,8:681875.
  • 加载中
计量
  • 文章访问数:  160
  • HTML全文浏览量:  3
  • PDF下载量:  66
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-10
  • 网络出版日期:  2022-03-19

目录

    /

    返回文章
    返回